Andexanet Alfa Withdrawn from the US Market

Thanks for the heads-up from Dr. Paul Riley, who commented on our December 27, 2025, post, Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal. Here is the press release from AstraZeneca announcing the withdrawal of andexanet alfa from the US market.

Comments (0)

Blog

Dec 27 2025

george

Clinical Trial: Thrombin Generation Test Predicts Breakthrough Bleeding in Emicizumab Prophylaxis

Check with your medical library to obtain this clinical trial pre-publication: Pelzer FJ, Ertekin EI, Oleshko O, et al. Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis. Haematologica. 2025. doi: 10.3324/haematol.2025.288115. PMID: 41230703. Abstract Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against […]

Bleeding Disorders

Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal

Navigate to this open-access article describing andexanet alfa reversal of LMWH: van Haaps TF, Benz AP, Xu L, Middeldorp S, Eikelboom JW, et al. Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin. Res Pract Thromb Haemost. 2025;9:103191. doi: 10.1016/j.rpth.2025.103191. PMID: 41141842; PMCID: PMC12552982. Abstract Background Andexanet alfa (andexanet) is the only approved reversal […]

Comments (1)

Anticoagulant Therapy

Dec 26 2025

george

August 2025 CAP Today: D-dimer Reporting and INR Are Variables That Matter

In follow-up to their July 2025 CAP Today article, A Deep Dive into Key Hemostasis Testing Variables, Drs. Andrew Goodwin and Eric Salazar present external quality improvement data on the PT–INR, D-dimer, and VET in their August 2025 article, D-dimer Reporting and INR Are Variables That Matter. Their article in particular examines the confusion over […]

Comments (0)

Anticoagulant Therapy

Dec 26 2025

george

Analytical Dilemmas in Lupus Anticoagulant Testing

Click here to read an open-access review by Moore GW. Analytical Dilemmas in Lupus Anticoagulant Testing. Explor Immunol. 2023;3:300–24 DOI: https://doi.org/10.37349/ei.2023.00104 Abstract Accurate lupus anticoagulant (LA) detection is crucial to antiphospholipid syndrome (APS) diagnosis. Detection is based on LA functional behavior in coagulation assays irrespective of epitope specificity. LA screening tests employ dilute phospholipids to […]

Arterial Thrombosis

AI in Thrombosis and Hemostasis

Here is an open-access article on the efficacy of artificial intelligence in hemostasis: Altememi MA, Favaloro EJ, Islam MZ, Santhakumar AB. Artificial intelligence and machine learning in thrombosis and hemostasis: a scoping review of clinical and laboratory applications, challenges, and future directions. Clin Chem Lab Med. 2025. doi: 10.1515/cclm-2025-1450. PMID: 41400592. Abstract This scoping review […]

Validation

Discussion of Phase I Data on a Unique anti-VWF Thrombolytic

A summary by Dr. Wolfgang Miesbach: A potential landmark thrombolytic innovation presented at ASH 2025. Thrilled by the exciting Phase 1 data presentation by Marie Scully and co-authors on TGD001, a groundbreaking novel von Willebrand factor (VWF)-targeting thrombolytic: First-of-its-kind mechanism: TGD001 is an antibody-enzyme fusion protein—specifically, an anti-VWF antibody fragment fused to a urokinase catalytic domain. […]

Arterial Thrombosis

Editorial: Thrombophilia Diagnosis–Genetic or Functional Testing

Check with your medical library for Favaloro EJ, Moore GW, Pasalic L. Diagnosing thrombophilia: the case for genetic or functional testing? Expert Rev Mol Diagn. 2025:1-6. doi: 10.1080/14737159.2025.2588621. PMID: 41211955. Introduction The term thrombophilia defines a condition in which there is an elevated risk of thrombosis, usually venous thromboembolism (VTE), generally encompassing deep vein thrombosis […]

Thrombophilia

Platelet Function Preservation Following Cell Salvage

Thanks to colleague Dave McGlasson, MS, MLS for identifying this open-access original research study that describes the effects of intraoperative cell salvage on platelet function. Blum LV, Sertdere F, Iken S, et al. Preservation of platelet function after intraoperative cell salvage using the i-SEP same device in cardiac surgery. J Cardiothorac Vasc Anesth. 2025:S1053-0770(25)01058-4. doi: […]

Comments (0)

Platelet Function Testing

Dec 11 2025

george

Thrombotic Thrombocytopenic Purpura Sequelae

An ASH ’25 summary by Dr. Wolfgang Miesbach: iTTP remission ≠ cure–the vascular injury persists. TTP as a cardiovascular disease equivalent. I just finished Dr. Senthil Sukumar’s session on long-term iTTP management. This completely changed how I think about these patients, as illustrated: 28.6% of survivors → major cardiovascular events 50% → silent cerebral infarcts (vs […]

Comments (0)

Thrombophilia

All Posts

Andexanet Alfa Withdrawn from the US Market

Clinical Trial: Thrombin Generation Test Predicts Breakthrough Bleeding in Emicizumab Prophylaxis

Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal

August 2025 CAP Today: D-dimer Reporting and INR Are Variables That Matter

Analytical Dilemmas in Lupus Anticoagulant Testing

AI in Thrombosis and Hemostasis

Discussion of Phase I Data on a Unique anti-VWF Thrombolytic

Editorial: Thrombophilia Diagnosis–Genetic or Functional Testing

Platelet Function Preservation Following Cell Salvage

Thrombotic Thrombocytopenic Purpura Sequelae

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question